Geron will get $35m up front and may earn up to $900m in milestone fees plus royalties on future sales of the telomerase inhibitor imetelstat under the biotechnology company's worldwide license and collaboration agreement with Johnson & Johnson's Janssen Biotech subsidiary.
November has been a good month for Menlo Park, California-based Geron, since the US FDA recently lifted a full clinical...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

